[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bariatric-sleeve-gastrectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bariatric-sleeve-gastrectomy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,83,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100597860","use-of-transcutaneous-electrical-nerve-stimulation-device-reletex-reliefband-with-current-eras-enhanced-recovery-after-surgery-protocol-to-further-decrease-postoperative-nausea-and-vomiting-in-the-bariatric-surgical-patient-within-the-first-24-hours-postoperatively-100597860",false,"NCT07063979","Use of Transcutaneous Electrical Nerve Stimulation Device, Reletex Reliefband, With Current ERAS (Enhanced Recovery After Surgery) Protocol to Further Decrease Postoperative Nausea and Vomiting in the Bariatric Surgical Patient Within the First 24 Hours Postoperatively.","Use of Transcutaneous Electrical Nerve Stimulation Device, Reletex Reliefband to Decrease Postoperative Nausea and Vomiting in the Bariatric Surgical Patient","Inclusion Criteria:\n\n* Adults 18-75 years of age\n* BMI 35 or greater\n* Patients eligible for and undergoing a Robotic Sleeve Gastrectomy\n* Able to consent on own behalf\n\nExclusion Criteria:\n\n* A diagnosis of gastroparesis\n* Pregnancy\n* Presence of a cardiac pacemaker\u002Fdefibrillator or intrathecal pump\n* Current smoker or tobacco use within 30 days of procedure.\n* Known allergic reactions to conductivity gel.\n\nDue to the nature of the Robotic Sleeve Gastrectomy patients who may be unable to follow or comprehend the long-term restrictions and\u002For requirements inherent of the surgery due to altered mentation are excluded from having the surgery.","ALL","18 Years","75 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if the Reletex Reliefband device when used in conjunction with our current treatments will further decrease postoperative nausea and vomiting. The Investigators want to test how well it works, specifically in bariatric surgery patients that are at a higher risk for nausea and vomiting after surgery. Furthermore, the investigators would like to see if using this non-drug treatment option might allow for the same or better control of nausea and vomiting with fewer side effects than the current medications used. This may decrease drowsiness, and allow for earlier mobility, increase comfort, and generally accelerate recovery after surgery.\n\nThe main questions it aims to answer are:\n\n* Does the use of Reletex Reliefband decrease postoperative nausea and vomiting (PONV) in the Bariatric surgical patient, therefore decreasing need for additional anti-emetics.\n* Does the use of Reletex Reliefband the use of the Reletex Reliefband during the immediate post-operative period reduce PONV, allowing for early mobility, decreased pain and length of stay (LOS).\n* Does the use of Reletex Reliefband decrease the use of medications for nausea and therefore decrease costs.\n* Does the use of Reletex Reliefband reduce prolonged PONV and therefore prevent the downstream effects, i.e. less mobility, increased pain, inhibit the patients' ability to comply with recommended treatments.\n* If reducing PONV using non-pharmaceutical approaches will improve outcomes and patient experiences.\n\nResearchers will compare to a placebo (a look-alike device) to see if the Reletex Reliefband works to decrease PONV.\n\nParticipants will:\n\n* All receive the standard Enhanced Recovery After Surgery (ERAS) Protocol before, during and after surgery. (This includes use of premedications for pain, and nausea)\n* Have a band applied and turned on at the completion of the patient's bariatric sleeve surgery. The band will be adjusted based on need and worn for a total of 24 hours postoperatively.\n* Have a pedometer clipped to their gown, to remain in place for 24 hours postoperatively\n* Be assessed regularly during their hospital stay by the nurses to monitor the site of the band, their level of nausea\u002Fvomiting, pain levels, and level of mobility",[27,28],"Postoperative Nausea and Vomiting","Bariatric Sleeve Gastrectomy",[30,31,32,33],"Prevention of Postoperative Nausea and Vomiting in Bariatric Patient","Reletex Reliefband to prevent PONV","Preventing PONV in Bariartic Postop patient","Reliefband","RECRUITING","2026-06-08",{"date":37,"type":38},"2026-06-10","ACTUAL",{"date":40,"type":38},"2025-11-04",{"date":42,"type":21},"2027-07",{"name":44,"class":45},"University of Pennsylvania","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":69,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":46},"100643122","the-effects-of-anesthesia-on-postoperative-cognitive-functions-in-patients-undergoing-sleeve-gastrectomy-100643122","NCT07637357","The Effects of Anesthesia on Postoperative Cognitive Functions in Patients Undergoing Sleeve Gastrectomy","The Effects of Total Intravenous Anesthesia and Inhalational Anesthesia on Postoperative Cognitive Functions in Patients Undergoing Sleeve Gastrectomy","Inclusion Criteria:\n\nPatients of both sexes, Patients Aged between 18 and 65 years, Patients classified as ASA(American Society of Anesthesiologists) physical status I- III, Patients with a BMI (Body Mass Index) between 35 and 50 kg\u002Fm² scheduled to undergo sleeve gastrectomy as a type of bariatric surgery for the first time.\n\nExclusion Criteria:\n\nPatients classified as ASA physical status 4 or high, Patients with known allergy to any of the drugs used in the study, Patients with bleeding disorders, Patients with serum creatinine levels \\>2 mg\u002FdL, Patients with severe arrhythmias and EF\\\u003C30%, Patients with a known history of drug abuse are excluded.","65 Years",{"count":56,"type":21},60,"3 Months","OBSERVATIONAL","In this study, the investigators want to examine the effects of intravenous anesthetic drugs and gases on cognitive functions in the postoperative period in individuals who will undergo surgery for obesity. The investigators believe that the anesthesia method we apply with inhalation gases is also as reliable method as total intravenous anesthesia for postoperative cognitive functions in these patients who undergoe sleeve gastrectomy.\n\nThe anesthesia method applied intravenously and with inahalational gases have been applied safely for many years. Comparisons between these two anesthesia technics in obese individuals and for postoperative cognitive dysfunctions are limited.\n\nStudies on the examination of cognitive functions in postoperative patients have gained momentum with the use of neuropsychiatric tests performed on patients who have undergone cardiac surgery and these tests have also been performed on individuals who have undergone non-cardiac surgery. And yet, similar declines in cognitive functions have been observed. For these reasons, the effects of surgery itself and anesthesia methods on cognitive functions have been studied up to date.\n\nIn this study, the investigators plan to evaluate patients who will undergo obesity surgery in both anesthesia methods by the recovery times from anesthesia and the residual effects of anesthesia, and after awakening they plan to evaluate their cognitive functions with neuropsychiatric tests that will be performed at certain intervals.",[61,62,63,64,28,65,66,67,68],"POCD - Postoperative Cognitive Dysfunction","Recovery Time","Postoperative Neurocognitive Disorder","Postoperative Delirium","Delayed Neurocognitive Recovery","Total Intravenous Anesthesia","Inhalational Anesthesia","Cognitive Functions",[70,71,72,73],"total intravenous anesthesia","inhalational anesthesia","sleeve gastrectomy","postoperative cognitive dysfunctions","2026-06-04",{"date":76,"type":38},"2026-06-09",{"date":78,"type":38},"2025-09-30",{"date":80,"type":21},"2026-07-30",{"name":82,"class":45},"Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":46},"100610683","bougie-diameter-on-outcomes-in-laparoscopic-sleeve-gastrectomy-100610683","NCT07230769","Bougie Diameter on Outcomes in Laparoscopic Sleeve Gastrectomy","Impact of Bougie Diameter on Outcomes in Laparoscopic Sleeve Gastrectomy - A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Adult patients aged between 18 and 70 years undergoing LSG as a primary bariatric procedure\n2. Body mass index (BMI) criteria according to 2022 ASMBS\u002FIFSO guidelines:\n\n   * BMI ≥35 kg\u002Fm² regardless of presence, absence, or severity of comorbidities, OR\n   * BMI 30-34.9 kg\u002Fm² (Class I obesity) with metabolic disease and inadequate response to nonsurgical methods, including:\n\n     * Type 2 diabetes mellitus\n     * Arterial hypertension\n     * Dyslipidemia\n     * Obstructive sleep apnea syndrome and other severe respiratory disorders\n     * Cardiovascular disease (coronary artery disease, heart failure, atrial fibrillation)\n     * Asthma\n     * Fatty liver disease and nonalcoholic steatohepatitis\n     * Chronic kidney disease\n     * Polycystic ovarian syndrome\n     * Infertility\n     * Pseudotumor cerebri\n     * Bone and joint diseases\n3. Decision for bariatric surgery approved after multidisciplinary team discussion\n4. Written informed consent obtained\n5. Ability to complete questionnaires and attend follow-up visits\n6. Stable weight (±5% for 3 months before surgery)\n7. Normal preoperative upper gastrointestinal endoscopy or findings limited to:\n\n   * Los Angeles (LA) Classification Grade A reflux esophagitis (minimal mucosal breaks \\\u003C5mm)\n   * Mild gastritis without active ulceration\n8. Negative or minimal gastroesophageal reflux symptoms (GERD-Q score ≤8)\n\nExclusion Criteria:\n\n1. History of previous gastric surgeries or bariatric procedures\n2. American Society of Anesthesiologists (ASA) score \\>4\n3. Ongoing pregnancy or planned pregnancy within the study period\n4. Significant esophageal and gastric pathology, including:\n\n   * Los Angeles (LA) Classification Grade B, C, or D reflux esophagitis\n   * Hiatal hernia or any paraesophageal hernia\n   * Barrett's esophagus of any length\n   * Active peptic ulcer disease\n   * Gastric polyps \\>1cm or suspicious lesions\n5. Severe gastroesophageal reflux disease is defined as:\n\n   * GERD-Q score \\>8\n   * Daily proton pump inhibitor (PPI) dependency with breakthrough symptoms\n   * Endoscopic evidence of LA Grade B, C, or D esophagitis\n6. Coagulation disorders or anticoagulation therapy that cannot be safely discontinued\n7. Known silicon hypersensitivity or allergies to bougie materials\n8. Active substance abuse or psychiatric conditions that may impair compliance","70 Years",{"count":20,"type":21},[24],"Laparoscopic sleeve gastrectomy (LSG) has become an increasingly popular bariatric procedure since its first performance by Hess and Hess in 1988 as a component of the biliopancreatic diversion-duodenal switch (BPD-DS) procedure, which was modified from Scopinaro's biliopancreatic diversion (BPD) and DeMeester's technique. In the early part of the twenty-first century, it was popularized as a first-step intervention before BPD or gastric bypass in the super obese and high-risk group of patients by Regan et al. Due to the unexpected good results in terms of weight loss and resolution of comorbidities, coupled with the simplicity of performing the procedure requiring intervention on only the stomach, sleeve gastrectomy gained status as a stand-alone bariatric procedure as demonstrated by Baltasar et al.\n\nThe basic principle of LSG is to create a narrow stomach along the lesser curvature, depending on the left gastric artery, using a calibration bougie as a template to perform a vertical partial gastrectomy, resecting the greater curvature and fundus of the stomach according to the International Sleeve Gastrectomy Expert Panel Consensus Statement by Rosenthal et al. The procedure has demonstrated excellent outcomes in terms of weight loss and comorbidity resolution, making it one of the most commonly performed bariatric procedures worldwide according to the IFSO Worldwide Survey by Angrisani et al.\n\nBougie Size Considerations and Rationale The selection of an appropriate bougie size during laparoscopic sleeve gastrectomy represents a critical technical decision that significantly influences both immediate surgical outcomes and long-term patient results. Calibration bougies serve as internal templates to standardize the gastric sleeve diameter and ensure consistent sleeve geometry across different surgeons and institutions, as described by Parikh et al.\n\nThe diameter of the bougie directly determines the final gastric volume and the degree of restriction achieved, which in turn affects weight loss efficacy, food tolerance, and complication rates.\n\nBougie sizes in current clinical practice typically range from 32-French (Fr) to 50-Fr, with most centers utilizing sizes between 34-Fr and 42-Fr according to the survey by Gagner et al. Small bougie sizes (32-36-Fr) create a more restrictive sleeve with potentially enhanced weight loss but may be associated with increased risks of stenosis, food intolerance, and gastroesophageal reflux disease as reported by Sakran et al.\n\nMedium bougie sizes (38-42-Fr) represent a compromise between restriction and safety, offering adequate weight loss while maintaining acceptable complication rates as demonstrated by Weiner et al. Large bougie sizes (44-50-Fr) provide greater sleeve capacity with improved food tolerance and potentially reduced leak rates, though concerns exist regarding long-term weight loss maintenance according to Abdallah et al.\n\nThe rationale for comparing different bougie sizes stems from the ongoing debate regarding the optimal balance between surgical efficacy and safety. Recent meta-analyses have suggested that larger bougie sizes may be associated with reduced gastric leak rates without significantly compromising weight loss outcomes. However, the majority of existing evidence comes from retrospective observational studies with inherent limitations including selection bias, confounding variables, and lack of standardized outcome measures as noted by Shi et al. The current study aims to provide definitive prospective evidence comparing small (36-Fr) versus X large (larger than 40-Fr) bougie sizes in a randomized controlled trial design.\n\nFurthermore, the impact of bougie size on comorbidity resolution remains inadequately studied. Bariatric surgery has demonstrated remarkable efficacy in resolving obesity-related comorbidities, with diabetes remission rates ranging from 53% to 63% as reported by Schauer et al. and hypertension resolution rates varying from 8% to 50% depending on the specific criteria used according to Sjöström et al. The relationship between sleeve geometry, as determined by bougie size, and comorbidity resolution mechanisms requires further investigation to optimize patient outcomes and surgical technique selection.",[28],[96,97],"Bougie Diameter","Outcomes in Laparoscopic Sleeve Gastrectomy","2026-02-14",{"date":100,"type":38},"2026-02-18",{"date":102,"type":38},"2026-02-15",{"date":104,"type":21},"2026-12",{"name":106,"class":107},"General Committee of Teaching Hospitals and Institutes, Egypt","OTHER_GOV",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":116,"sex":16,"minAge":17,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":128,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":46},"100617855","chrono-align-a-chronotype-based-chrono-nutrition-intervention-in-post-bariatric-patients-100617855","NCT07324044","Chrono-ALIGN: A Chronotype-Based Chrono-Nutrition Intervention in Post-Bariatric Patients","Chrono-ALIGN Trial: The Impact of Chronotype-Based Chrono-Nutrition on Metabolic Health, Gut Microbiota, Appetite, and Circadian Alignment in Post-Bariatric Surgery Patients: A Randomized Controlled Trial","Chrono-ALIGN","Inclusion Criteria:\n\n* Adults aged 18-50 years who underwent Sleeve Gastrectomy (SG) 6 Months prior to enrollment.\n* Have achieved ≥50% of excess weight loss post-surgery (to ensure initial success).\n* Current BMI between 25-40 kg\u002Fm².\n* No major postoperative complications and cleared for a regular diet by their healthcare provider.\n* Participants must be able to align their eating schedule within a daytime window (morning to evening), ensuring that the first meal is consumed in the early part of the day and the last meal is completed before late evening, in accordance with chrono-nutrition guidelines.\n\nExclusion Criteria:\n\n* • Pregnancy or planned pregnancy during the study period, and post menopaused females\n\n  * Current diagnosis of severe psychiatric illness that may interfere with adherence (e.g., untreated major depression, psychosis, severe eating disorders).\n  * Active malignancy or serious chronic disease unrelated to obesity that may confound outcomes (e.g., advanced renal failure, uncontrolled liver disease).\n  * Use of medications known to significantly alter circadian rhythm or metabolism (e.g., corticosteroids, melatonin therapy) within the last 3 months.\n  * Inability to comply with study requirements (dietary interventions, sample collection, or follow-up visits).Participants who have previously undergone revision bariatric surgery.\n  * Individuals following intermittent fasting regimens prior to the study.",true,"50 Years",{"count":119,"type":21},246,[24],"This randomized controlled trial will evaluate the impact of chrono-nutrition, a dietary approach that aligns meal timing with the body's circadian rhythms, on weight change, metabolic outcomes, appetite, and gut microbiota in post-bariatric surgery patients. A total of 246 adults who underwent sleeve gastrectomy at least six months earlier will be enrolled at King Saud Medical City. Participants will be randomized to receive either standard post-bariatric nutritional care or personalized chrono-nutrition based on individual chronotype. Outcomes include weight change, metabolic biomarkers, dietary behaviors, sleep patterns, and gut microbiota composition. The study aims to determine whether integrating chrono-nutrition into post-bariatric follow-up can enhance metabolic health and improve long-term health.",[123,124,28,125,126,127],"Obesity (Disorder)","Morbid Obesity","Meal Time","Chronotype","Circadian Rhythm",[129,130,131,132,133,134],"chrononutrition","Bariatric Surgery","Gastric Sleeve","Gut Microbiota","Appetite","Meal Timing","NOT_YET_RECRUITING","2025-12-23",{"date":138,"type":38},"2026-01-07",{"date":140,"type":21},"2026-01-01",{"date":142,"type":21},"2028-12-01",{"name":144,"class":45},"King Saud University"]